What is HC Wainwright’s Forecast for FBIO Q4 Earnings?

Fortress Biotech, Inc. (NASDAQ:FBIO) – Research analysts at HC Wainwright issued their Q4 2024 EPS estimates for Fortress Biotech in a research report issued to clients and investors on Monday, November 18th. HC Wainwright analyst J. Pantginis forecasts that the biopharmaceutical company will post earnings per share of ($0.83) for the quarter. HC Wainwright has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for Fortress Biotech’s current full-year earnings is ($2.65) per share. HC Wainwright also issued estimates for Fortress Biotech’s FY2025 earnings at ($1.38) EPS, FY2026 earnings at ($1.07) EPS and FY2027 earnings at ($0.46) EPS.

Separately, StockNews.com downgraded Fortress Biotech from a “hold” rating to a “sell” rating in a report on Friday, November 15th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $13.67.

Fortress Biotech Price Performance

NASDAQ:FBIO opened at $1.57 on Wednesday. The stock has a market capitalization of $43.33 million, a PE ratio of -0.51 and a beta of 1.75. Fortress Biotech has a fifty-two week low of $1.36 and a fifty-two week high of $4.43. The business’s 50-day simple moving average is $1.69 and its 200-day simple moving average is $1.83.

Insider Transactions at Fortress Biotech

In other Fortress Biotech news, CEO Lindsay A. Md Rosenwald bought 763,359 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The shares were acquired at an average cost of $1.84 per share, with a total value of $1,404,580.56. Following the acquisition, the chief executive officer now owns 3,657,264 shares of the company’s stock, valued at $6,729,365.76. The trade was a 26.38 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 33.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Fortress Biotech

Several institutional investors and hedge funds have recently modified their holdings of FBIO. Virtu Financial LLC acquired a new position in shares of Fortress Biotech in the first quarter valued at approximately $31,000. Integrated Wealth Concepts LLC grew its holdings in Fortress Biotech by 68.2% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 46,100 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 18,700 shares in the last quarter. 180 Wealth Advisors LLC acquired a new stake in shares of Fortress Biotech during the second quarter worth $107,000. Atria Investments Inc boosted its position in shares of Fortress Biotech by 58.4% in the third quarter. Atria Investments Inc now owns 71,484 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 26,351 shares during the period. Finally, B. Riley Wealth Advisors Inc. bought a new stake in shares of Fortress Biotech in the second quarter valued at about $207,000. 96.51% of the stock is currently owned by institutional investors and hedge funds.

Fortress Biotech Company Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.